English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The effects of carteolol, propranolol and alprenolol were studied by using spontaneously contracting atria, atrial muscle and papillary muscle prepared from rat hearts. Propranolol, alprenolol and carteolol caused decreases in atrial rate and in contractile tension of electrically driven cardiac muscles in concentrations of 10(-6) to 10(-5) g/ml, 10(-6) to 10(-5) g/ml and 10(-4) g/ml, respectively. These compounds, also, effectively prevented electrically-induced atrial arrhythmias in these concentrations. Contractile tension of the cardiac muscles was increased by carteolol in concentrations of 10(-7) to 10(-6) g/ml. The refractory period of the cardiac muscles was prolonged in the presence of alprenolol (10(-7) to 10(-6) g/ml) or carteolol (10(-6) to 10(-5) g/ml). The refractory period of the papillary muscle was increased by 10(-7) to 10(-6) g/ml of propranolol. The maximum driven frequency (MDF) of the atrial muscle was reduced by 5X10(-8) to 10(-7) g/ml of carteolol or by 5X10(-8) g/ml of alprenolol, and MDF of the papillary muscle by 5X10(-7) g/ml of propranolol. In extremely high concentrations, these compounds significantly reduced MDF of the cardiac muscle. These results suggest that the antiarrhythmic action of alprenolol and carteolol is more predominant in atria than in ventricles, whereas the reverse is true for propranolol.

A comparison of the effects of the beta-adrenergic blockers, carteolol (OPC-1085), propranolol and alprenolol on isolated rat cardiac muscles